



## **Sienna Cancer Diagnostics Appoints Helen Fisher to Board**

**Melbourne, Australia, 26 March 2018:** Sienna Cancer Diagnostics Ltd (ASX:SDX) (“Sienna” or “The Company”), a medical technology company developing and commercialising innovative cancer-related tests, is pleased to announce the appointment of Helen Fisher as an Independent Non-Executive Director and Chair of the Audit and Risk Committee, effective 28 March 2018.

Sienna’s Chairman, Geoff Cumming said “We are very pleased to welcome Helen to Sienna’s Board. She brings great financial acumen, including accounting and taxation expertise, which, combined with her deep knowledge of the Life Sciences industry and her extensive network in the investment community, make Helen a valuable addition to our Board.”

Previously a partner at Deloitte for 10 years, Ms Fisher has an exemplary track record, including leading Deloitte Australia’s Life Sciences Industry team and advising many Life Sciences and Biotechnology companies.

In July 2017, Ms Fisher established a new global Life Sciences fund, Bio Capital Impact Fund, investing in disruptive, high-growth Life Science and Biotechnology companies. She has also worked with the Australian Government and industry associations to achieve positive policy changes for the sector. Additionally, Ms Fisher has advised on the effective tax management of intellectual property, mergers and acquisition and product licensing, all areas of great relevance to Sienna.

On joining Sienna, Ms Fisher said: “I am delighted to join Sienna’s Board and look forward to contributing to the worldwide commercialisation of the Company’s technology and working alongside Sienna’s team in growing the Company.”

- ENDS -

### **For further information, please contact:**

Matthew Hoskin, CEO  
Sienna Cancer Diagnostics  
mhoskin@siennadiagnostics.com.au  
+61 3 8288 2141

Kyahn Williamson  
WE Buchan  
kwilliamson@we-buchan.com  
+61 3 9866 4722

### **About Sienna Cancer Diagnostics**

Sienna Cancer Diagnostics Ltd. is an Australian medical technology company, with operations in the United States, Europe and Australia. Sienna’s strengths lie in identifying novel technologies that satisfy an unmet clinical / market need, then developing and commercialising them. The Company has demonstrated the utility of its first product with the help of its global clinical partners. Sienna’s primary platform is the detection of the biomarker telomerase, which is found in nearly all epithelial cancers, and was the subject of a Nobel Prize in 2009. Telomerase is well recognised as an important biomarker used by 85% of cancers to enable immortal cell replication.

The FDA listing of Sienna’s first IVD in the United States, and CE marking / IVD registration in Europe and Australia, means the SCD-A7 reagent can be used for clinical diagnostic purposes by pathology laboratories in those regions. Diagnostic pathology laboratories may now purchase the product for use as an in-vitro diagnostic test for the presence of hTERT, a component of telomerase.